X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs SANOFI INDIA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. SANOFI INDIA FRESENIUS KABI ONCO./
SANOFI INDIA
 
P/E (TTM) x 22.1 39.5 56.1% View Chart
P/BV x 3.1 8.5 36.6% View Chart
Dividend Yield % 0.0 1.1 -  

Financials

 FRESENIUS KABI ONCO.   SANOFI INDIA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
SANOFI INDIA
Dec-16
FRESENIUS KABI ONCO./
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1764,560 3.9%   
Low Rs794,400 1.8%   
Sales per share (Unadj.) Rs37.71,028.5 3.7%  
Earnings per share (Unadj.) Rs5.1129.0 3.9%  
Cash flow per share (Unadj.) Rs6.7186.0 3.6%  
Dividends per share (Unadj.) Rs068.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs42.5753.6 5.6%  
Shares outstanding (eoy) m158.2323.03 687.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.4 77.5%   
Avg P/E ratio x25.034.7 71.9%  
P/CF ratio (eoy) x18.924.1 78.6%  
Price / Book Value ratio x3.05.9 50.3%  
Dividend payout %052.7 0.0%   
Avg Mkt Cap Rs m20,135103,174 19.5%   
No. of employees `0001.23.6 31.8%   
Total wages/salary Rs m7033,592 19.6%   
Avg. sales/employee Rs Th5,176.26,537.7 79.2%   
Avg. wages/employee Rs Th610.4991.4 61.6%   
Avg. net profit/employee Rs Th699.6819.8 85.3%   
INCOME DATA
Net Sales Rs m5,96323,686 25.2%  
Other income Rs m18708 2.5%   
Total revenues Rs m5,98124,394 24.5%   
Gross profit Rs m1,4305,281 27.1%  
Depreciation Rs m2581,313 19.6%   
Interest Rs m-2615 -173.3%   
Profit before tax Rs m1,2164,661 26.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3421,691 20.2%   
Profit after tax Rs m8062,970 27.1%  
Gross profit margin %24.022.3 107.6%  
Effective tax rate %28.136.3 77.6%   
Net profit margin %13.512.5 107.8%  
BALANCE SHEET DATA
Current assets Rs m5,10215,673 32.6%   
Current liabilities Rs m2,3856,678 35.7%   
Net working cap to sales %45.638.0 119.9%  
Current ratio x2.12.3 91.1%  
Inventory Days Days15076 197.4%  
Debtors Days Days11322 507.7%  
Net fixed assets Rs m5,1488,098 63.6%   
Share capital Rs m158230 68.7%   
"Free" reserves Rs m6,55617,088 38.4%   
Net worth Rs m6,73217,356 38.8%   
Long term debt Rs m9520-   
Total assets Rs m10,38825,400 40.9%  
Interest coverage x-45.8311.7 -14.7%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.60.9 61.6%   
Return on assets %7.511.8 63.9%  
Return on equity %12.017.1 70.0%  
Return on capital %14.626.9 54.2%  
Exports to sales %74.524.5 304.1%   
Imports to sales %24.828.0 88.6%   
Exports (fob) Rs m4,4415,801 76.5%   
Imports (cif) Rs m1,4776,627 22.3%   
Fx inflow Rs m5,2987,145 74.1%   
Fx outflow Rs m1,7726,846 25.9%   
Net fx Rs m3,525299 1,179.1%   
CASH FLOW
From Operations Rs m1,2743,226 39.5%  
From Investments Rs m-1,204-1,555 77.4%  
From Financial Activity Rs m-196-1,818 10.8%  
Net Cashflow Rs m-126-147 85.9%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 81.0 60.4 134.1%  
Indian inst/Mut Fund % 0.3 14.4 2.1%  
FIIs % 9.6 14.6 65.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.5 86.7%  
Shareholders   42,599 15,184 280.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   WOCKHARDT LTD.  J.B.CHEMICALS  ORCHID PHARMA LTD  BIOCON LTD  FULFORD INDIA  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Weak; FMCG Stocks Drag(12:30 pm)

Stock markets in India are trading in negative territory weighed by fast-moving consumer goods (FMCG) stocks.

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY18); Net Profit Up 37.5% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, SANOFI INDIA has posted a net profit of Rs 825 m (up 37.5% YoY). Sales on the other hand came in at Rs 6 bn (up 11.7% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS